Literature DB >> 6335388

Lymphoid abnormalities in rats with adjuvant-induced arthritis. I. Mitogen responsiveness and lymphokine synthesis.

S C Gilman, J F Daniels, R E Wilson, R P Carlson, A J Lewis.   

Abstract

Lewis rats injected in the hind paw with Mycobacterium butyricum develop a severe polyarthritis which shares certain features in common with rheumatoid arthritis in man. Spleen and peripheral blood mononuclear cells from rats with this form of arthritic disease proliferate poorly in vitro in response to concanavalin A (con A), phytohaemagglutinin (PHA), and pokeweed mitogen (PWM). The splenic hyporesponsiveness appears within four days of M. butyricum injection (three to five days prior to the development of detectable arthritis), reaches a peak 16-22 days following injection, and persists for at least 40 days. Buffalo strain rats injected with M. butyricum do not develop arthritis, and their spleen cells respond normally to con A, PHA, and PWM. In response to lipopolysaccharide (LPS) the synthesis of interleukin 1 (IL-1) by spleen or peritoneal macrophages from arthritic Lewis rats equalled or exceeded that of macrophages from normal rats. In contrast splenic T cells from arthritic rats produced reduced amounts of interleukin 2 (IL-2; T cell growth factor) in response to stimulation with PHA or con A. Moreover, con-A-activated spleen cells from arthritic rats failed to bind IL-2 and to respond to this growth factor with increased 3H-TdR uptake as did normal spleen cells. In-vitro treatment of 'arthritic' cells with 10(-5) M indomethacin did not restore to normal their reduced mitogen responsiveness, and spleen cells from normal and arthritic rats were equally sensitive to the inhibitory effects of prostaglandin E2 on con-A-induced proliferative responses. These results indicate that peripheral lymphoid function is compromised in rats with adjuvant-induced arthritis and that this functional deficit is mediated by aberrant synthesis of and response to IL-2 by T cells of arthritic animals.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6335388      PMCID: PMC1001550          DOI: 10.1136/ard.43.6.847

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  30 in total

1.  Altered regulation of Epstein-Barr virus induced lymphoblast proliferation in rheumatoid arthritis lymphoid cells.

Authors:  P A Bardwick; H G Bluestein; N J Zvaifler; J M Depper; J E Seegmiller
Journal:  Arthritis Rheum       Date:  1980-06

2.  Active suppression of in vitro reactivity of spleen cells after BCG treatment.

Authors:  S Orbach-Arbouys; M F Poupon
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

Review 3.  The immunopathology of joint inflammation in rheumatoid arthritis.

Authors:  N J Zvaifler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

4.  Lymphocytes in rheumatoid arthritis. I. Responses to allogeneic cells and to phytomitogens.

Authors:  A J Rawson; T C Huang
Journal:  Clin Exp Immunol       Date:  1974-01       Impact factor: 4.330

5.  Effect of Freund's adjuvant on the mitogenic responses of rat lymphocytes.

Authors:  L Kourounakis; M A Kapusta
Journal:  Ann Rheum Dis       Date:  1974-03       Impact factor: 19.103

Review 6.  T-cell growth factor.

Authors:  K A Smith
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

Review 7.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; D R Webb
Journal:  Clin Immunol Immunopathol       Date:  1980-01

8.  Altered lymphocyte reactivity in rheumatoid arthritis.

Authors:  H A Silverman; J S Johnson; J H Vaughan; J C McGlamory
Journal:  Arthritis Rheum       Date:  1976 May-Jun

9.  The antiinflammatory profile of (5H-dibenzo[a,d]-cyclohepten-5-ylidene)acetic acid (WY-41,770), an agent possessing weak prostaglandin synthetase inhibitory activity that is devoid of gastric side effects.

Authors:  R P Carlson; L J Datko; J Chang; S T Nielsen; A J Lewis
Journal:  Agents Actions       Date:  1984-06

10.  The modifying effect of BCG on the immunological induction of T cells.

Authors:  G B Mackaness; P H Lagrange; T Ishibashi
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

View more
  7 in total

1.  Interleukin production in juvenile chronic arthritis.

Authors:  G R Burgio; A Martini
Journal:  Ann Rheum Dis       Date:  1985-10       Impact factor: 19.103

2.  Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.

Authors:  P Hambleton; S McMahon
Journal:  Agents Actions       Date:  1990-03

3.  Optimization of Folate-Targeted Immunotherapy for the Treatment of Experimental Arthritis.

Authors:  Bindu Varghese; Chrystal Paulos; Philip S Low
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

4.  Alteration of interleukin-1 activity and the acute phase response in adjuvant arthritic rats treated with disease modifying antirheumatic drugs.

Authors:  K M Connolly; V J Stecher; E Danis; D J Pruden; T LaBrie
Journal:  Agents Actions       Date:  1988-08

5.  Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis.

Authors:  A Shore; S Jaglal; E C Keystone
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

6.  Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-kappaB binding activity and TNF-alpha secretion of T cells.

Authors:  Dirk Pohlers; Carsten B Schmidt-Weber; Angels Franch; Jürgen Kuhlmann; Rolf Bräuer; Frank Emmrich; Raimund W Kinne
Journal:  Arthritis Res       Date:  2002-01-08

7.  Reactivity of rat bone marrow-derived macrophages to neurotransmitter stimulation in the context of collagen II-induced arthritis.

Authors:  Dominique Muschter; Claudia Göttl; Mandy Vogel; Joachim Grifka; Rainer H Straub; Susanne Grässel
Journal:  Arthritis Res Ther       Date:  2015-06-24       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.